Central States Research, LLC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$66,961	10
2024	Research	$58,195	29
2023	Research	$123,756	25
2022	Research	$92,612	11
2021	Research	$17,126	8
2020	Research	$65,483	5

Breakdown

Who paid Research payments · program years 2020–2025

Novo Nordisk AS $329,793 81 payments
Ucb SA $60,100 2 payments
E.R. Squibb & Sons, L.L.C. $21,318 1 payment
Celgene Corporation $11,716 2 payments
Teva Pharmaceuticals USA, Inc. $1,206 2 payments

Studies the money was for Research payments · program years 2020–2025

Nn6535-4725 $329,793 81 payments
A Phase 3, Randomized, Double-Blind, Placebocontrolled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa $60,100 2 payments
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Agitation Associated with Alzheimers Disease $21,318 1 payment
Induction Study #2 - A Phase 3, Multicenter, Rando $7,539 1 payment
PhIII Yellowstone Induction Study # 2 OZANIMOD in Moderate to Severe CD (RPC01-3202) (BMS Study Number: IM047-P15) $4,176 1 payment
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age $1,206 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.